Cover Image
市場調查報告書

抗體醫藥品:技術及全球市場

Antibody Drugs: Technologies and Global Markets

出版商 BCC Research 商品編碼 230632
出版日期 內容資訊 英文 115 Pages
訂單完成後即時交付
價格
Back to Top
抗體醫藥品:技術及全球市場 Antibody Drugs: Technologies and Global Markets
出版日期: 2017年10月01日 內容資訊: 英文 115 Pages
簡介

本報告提供抗體醫藥品的全球市場為焦點、各種抗體藥領域的成長性品質、數量兩方面評估、今後的方向性與發展規模展望、性各種技術問題和競爭企業、關於此產品的最新分析資訊送交。

第1章 簡介 - 序

  • 調查的最後目標和中間指標
  • 背景調查
  • 主要讀者
  • 報告的範圍
  • 資訊來源
  • 關於分析師
  • 相關報告
  • BCC線上服務
  • 免責聲明

第2章 摘要

  • 摘要表:全球抗體治療藥市場(各地區)
  • 摘要圖:全球抗體治療藥市場(各地區)

第3章 概要

  • 定義
  • 單克隆抗體醫藥品
    • 單克隆抗體醫藥品的歷史
    • 單克隆抗體醫藥品的種類
    • 單克隆抗體醫藥品的製造技術
    • 單克隆抗體醫藥品的使用

第4章 法規方面

  • 回收
  • 新藥的申請/生物製藥核准
  • 安全警報

第5章 開發

  • 第Ⅰ階段實驗
  • 第Ⅱ階段實驗
  • 第Ⅲ階段實驗
  • 第Ⅳ階段實驗
  • M&A

第6章 市場分析

  • 各類型
  • 各地區
  • 各製造工程

第7章 用途

  • 各疾病市場
  • 全球抗體醫藥品市場;各疾病
    • 市場佔有率
    • 自體免疫疾病
    • 固態腫瘤
    • 淋巴瘤及白血病
    • 其他

第8章 產業結構

  • 小鼠單克隆抗體
    • 產業領導者
    • 市場佔有率
  • 嵌合體化單克隆抗體
  • 人體化單克隆抗體
  • 人類單克隆抗體

第9章 專利分析

  • 各年度專利數量
  • 各種類/類別
  • 各企業
  • 各國
  • 各申請人

第10章 現狀

  • 技術、技術的問題點
    • HAMA(人類的抗小鼠抗體)問題
    • 人體化、嵌合體化、基因改造抗體的優勢點
  • 正在開發的抗體技術
  • 應對治療方法的其他抗體的優勢點
  • 單克隆抗體醫藥品市場的影響因素

第11章 企業簡介

  • ABBOTT LABORATORIES
  • ALEXION PHARMACEUTICALS
  • AMGEN
  • BIOGEN IDEC
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND CO.
  • GLAXOSMITHKLINE
  • HOFFMAN-LA ROCHE
  • JOHNSON & JOHNSON
  • MERCK & CO.
  • MERCK KGAA
  • NOVARTIS
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS
  • TAKEDA PHARMACEUTICAL U.S.A. INC.
  • UCB COMPANY

第12章 附錄:簡稱一覽

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO016K

The global market for antibody drugs reached $80.8 billion in 2016. The market should reach $114.6 billion by 2022 increasing from $84.5 billion in 2017, at a compound annual growth rate (CAGR) of 6.3% from 2017 through 2022.

Report Includes

  • An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
  • Analyses of global market trends, with data from 2014, 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
  • Analysis and assessment of the therapeutic applications of mAbs in human medicine.
  • A look at the antibody industry as a whole, as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
  • Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industries in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

Report Scope

This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.

BCC Research analyzes and makes projections for each market and its applications, the regulatory environment, new products and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd. and Merck & Co.

The report covers the major markets of the U.S. and Europe, as well as emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.

Monoclonal antibodies are protein-based therapies/drugs that are finding use in the treatment of number of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human and humanized antibodies.

Excluded from this report are polyclonal antibodies; screening kits; and diagnostic uses of mAbs. Also excluded are research applications of mAbs and therapeutic antibodies for veterinary use.

Analyst Credentials

SHALINI DEWAN focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master\'s degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Antibodies and Antigens
  • Antibody Functions
  • Monoclonal Antibodies
    • History of Monoclonal Antibodies
    • Advantages and Disadvantages of Monoclonal Antibodies
    • Types of Monoclonal Antibodies
    • Manufacturing Technologies of Monoclonal Antibodies
    • Applications of Monoclonal Antibodies

Chapter 4: Market Breakdown by Technology Type

  • Market by Type
    • Market Overview
    • Market Revenue
    • Market Share
  • Market by Region
    • Market Overview
    • Market Revenue
    • Market Share
    • Murine Monoclonal Antibodies
    • Chimeric Monoclonal Antibodies
    • Human Monoclonal Antibodies
    • Humanized Monoclonal Antibodies
  • Market by Manufacturing Process
    • Market Overview
    • Market Revenue
    • Market Share
    • Market of Murine Monoclonal Antibodies by Manufacturing Process
    • Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process
    • Market Analysis of Human Monoclonal Antibodies by Manufacturing Process
    • Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process

Chapter 5: Market Breakdown by Application

  • Market by Diseases
    • Market Overview
    • Market Revenue
    • Market Share
    • Autoimmune Disease
    • Solid Tumors
    • Lymphoma and Leukemia
    • Others

Chapter 6: Industry Structure

  • Murine Monoclonal Antibodies
    • Market Leaders
    • Market Share
  • Chimeric Monoclonal Antibodies
    • Market Leaders
    • Market Share
  • Humanized Monoclonal Antibodies
    • Market Leaders
    • Market Share
  • Human Monoclonal Antibodies
    • Market Leaders
    • Market Share

Chapter 7: Regulatory Aspects

  • New Approvals of Monoclonal Antibodies
  • Recalls
  • Safety Alerts

Chapter 8: Patent Review/ New Developments

  • Patent Review
    • Patents by Year
    • Patents by Type
    • Patents by Company.
    • Patents by Country
    • Patents by Assignee
  • New Developments
    • Phase I clinical trials
    • Phase II clinical trials
    • Phase III Clinical Trials
    • Phase IV Clinical Trials
  • Mergers and Acquisitions

Chapter 9: Analysis of Market Opportunities

  • Technical Issues
  • Human anti-mouse antibody (HAMA) Problem
  • Factors Affecting mAb Drugs
    • Increasing Prevalence of Chronic Diseases
    • Aging Population
    • Price Regulation
    • Regulatory Approvals
    • Increasing Competition between Drug Makers
    • Advances in Manufacturing Technologies
    • Biosimilars
    • Mergers and Acquisitions
    • Licensing Agreements

Chapter 10: Company Profiles

Appendix: Abbreviations

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table Global Market for Antibody Drugs, by Disease, Through 2022 ($ Millions)
  • Table 1 Evolution of Monoclonal Antibodies
  • Table 2 Advantages and Disadvantages of Monoclonal Antibodies
  • Table 3 Murine Monoclonal Antibodies
  • Table 4 Chimeric Monoclonal Antibodies
  • Table 5 Humanized Monoclonal Antibodies
  • Table 6 Human Monoclonal Antibodies
  • Table 7 Differences between Hybridoma and Recombinant Technologies
  • Table 8 Murine Monoclonal Antibodies and Their Applications
  • Table 9 Chimeric Monoclonal Antibodies and Their Applications
  • Table 10 Human Monoclonal Antibodies and Their Applications.
  • Table 11 Humanized Monoclonal Antibodies and Their Applications
  • Table 12 Global Sales of Antibody Drugs, by Type, Through 2022 ($ Millions)
  • Table 13 Market Shares for Antibody Drugs, by Type, 2016 (%)
  • Table 14 Global Sales of Antibody Drugs, by Region, Through 2022 ($ Millions)
  • Table 15 Market Shares for Antibody Drugs, by Region, 2016 (%)
  • Table 16 Global Market for Murine Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
  • Table 17 Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
  • Table 18 Global Market for Human Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
  • Table 19 Global Market for Humanized Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
  • Table 20 Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 21 Market Shares for Antibody Drugs, by Manufacturing Process, 2016 (%)
  • Table 22 Global Market for Murine Antibody Drugs, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 23 Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 24 Global Market for Human Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 25 Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 26 Global Sales of Antibody Drugs, by Disease, Through 2022 ($ Millions)
  • Table 27 Market Shares for Antibody Drugs, by Disease, 2016 (%)
  • Table 28 Types of Autoimmune Diseases
  • Table 29 Global Market for Antibody Drugs in Autoimmune Diseases, by Type, Through 2022 ($ Millions)
  • Table 30 Global Market for Antibody Drugs in Autoimmune Diseases, by Region, Through 2022 ($ Millions)
  • Table 31 Types of Cancer by the Tissue of Origin
  • Table 32 Global Market for Antibody Drugs in Solid Tumors, by Type, Through 2022 ($ Millions)
  • Table 33 Global Market for Antibody Drugs in Solid Tumors, by Region, Through 2022 ($ Millions)
  • Table 34 Types of Leukemia
  • Table 35 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Type, Through 2022 ($ Millions)
  • Table 36 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Region, Through 2022 ($ Millions)
  • Table 37 Global Market for Antibody Drugs in Other Diseases, by Type, Through 2022 ($ Millions)
  • Table 38 Global Market for Antibody Drugs in Other Diseases, by Region, Through 2022 ($ Millions)
  • Table 39 Leading Manufacturer of Murine Monoclonal Antibodies, 2016
  • Table 40 Leading Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016
  • Table 41 Market Shares of Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 (%)
  • Table 42 Leading Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016
  • Table 43 Market Shares of Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 (%)
  • Table 44 Leading Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016
  • Table 45 Market Shares of Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016 (%)
  • Table 46 New Approvals of Monoclonal Antibodies, 2014-January 2017
  • Table 47 Recalls, 2014-January 2017
  • Table 48 Safety Alerts, 2014-January 2017
  • Table 49 Number of Patents, by Year, 2014-January 2017
  • Table 50 Number of Patents, by Type, 2014-January 2017
  • Table 51 Number of Patents, by Company, 2014-January 2017
  • Table 52 Number of Patents, by Country, 2014-January 2017
  • Table 53 Share of Patents by Country, 2014-January 2017 (No./%)
  • Table 54 Number of Patents, by Assignee, 2014-January 2017.
  • Table 55 Monoclonal Antibodies in Phase I Clinical Trials
  • Table 56 Monoclonal Antibodies in Phase II Clinical Trials
  • Table 57 Monoclonal Antibodies in Phase III Clinical Trials
  • Table 58 Monoclonal Antibodies in Phase IV Clinical Trials
  • Table 59 Mergers and Acquisitions of Top Pharmaceutical Companies, 2014-January 2017
  • Table 60 Abbreviations Used in the Antibody Drug Industry

List of Figures

  • Summary Figure Global Market for Antibody Drugs, by Disease, 2014-2022 ($ Millions)
  • Figure 1 Global Sales of Antibody Drugs, by Type, 2014-2022 ($ Millions)
  • Figure 2 Market Shares of Antibody Drugs, by Type, 2016 (%)
  • Figure 3 Global Sales of Antibody Drugs, by Region, 2014-2022 ($ Millions)
  • Figure 4 Market Shares for Antibody Drugs, by Region, 2016 (%)
  • Figure 5 Global Market for Murine Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
  • Figure 6 Global Market for Chimeric Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
  • Figure 7 Global Market for Human Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
  • Figure 8 Global Market for Humanized Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
  • Figure 9 Global Market for Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 10 Market Shares for Antibody Drugs, by Manufacturing Process, 2016 (%)
  • Figure 11 Global Market for Murine Antibody Drugs, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 12 Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 13 Global Market for Human Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 14 Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 15 Global Sales of Antibody Drugs, by Disease, 2014-2022 ($ Millions).
  • Figure 16 Market Shares for Antibody Drugs, by Disease, 2016 (%)
  • Figure 17 Global Market for Antibody Drugs in Autoimmune Diseases, by Type, 2014-2022 ($ Millions)
  • Figure 18 Global Market for Antibody Drugs in Autoimmune Diseases, by Region, 2014-2022 ($ Millions)
  • Figure 19 Global Market for Antibody Drugs in Solid Tumors, by Type, 2014-2022 ($ Millions)
  • Figure 20 Global Market for Antibody Drugs in Solid Tumors, by Region, 2014-2022 ($ Millions)
  • Figure 21 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Type, 2014-2022 ($ Millions)
  • Figure 22 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Region, 2014-2022 ($ Millions)
  • Figure 23 Global Market for Antibody Drugs in Other Diseases, by Type, 2014-2022 ($ Millions)
  • Figure 24 Global Market for Antibody Drugs in Other Diseases, by Region, Through 2022 ($ Millions)
  • Figure 25 Market Shares of Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 (%)
  • Figure 26 Market Shares of Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 (%)
  • Figure 27 Market Share of Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016 (%)
  • Figure 28 Number of Patents, by Year, 2014-January 2017
  • Figure 29 Number of Patents, by Type, 2014-January 2017
  • Figure 30 Share of Patents, by Country, 2014-January 2017 (%)
  • Figure 31 Number of Patents, by Assignee, 2014-January 2017
Back to Top